Archive | October, 2017

RESI JPM 2018 Early Bird Registration Is Open

26 Oct

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On January 9th, 2018, the Redefining Early Stage Investments (RESI) Conference will join the JPM fray again for our largest event yet in San Francisco.

In the last two RESI JPM conferences, we had to close registrations two weeks early as we’d reached capacity. In RESI JPM 2018, LSN is expecting to bring together 500+ fundraising CEOs and 500+ early stage investors from around the globe and host over 2000 scheduled and ad hoc meetings in one high energy day.

RESI JPM will offer early stage companies and investors an opportunity to get the most out of the wild week when the biotech and medtech world gathers by the Bay. Register early to secure your partnering meetings with investors and strategic partners that are a fit.

LSN Mapped the Life Science Infrastructure in NYC – Here’s What We Found

26 Oct

By Lucy Parkinson, Director of Research, LSN

When LSN decided to launch our first RESI NYC event, we knew that RESI would be part of a growing hub of resources dedicated to launching and supporting new biotech and medtech companies. The rise of NYC has been an ongoing story in the biotech world, and we’ve written before about how the city stands among the competitors to become North America’s third great life science hub.

For a long time, the New Jersey area has been a center for big pharma companies, and New York’s universities and research hospitals have long been a significant source of scientific breakthroughs in the life sciences. All told, we counted 80 pharma facilities, and almost all of these are located outside the city. Conversely, of the 32 relevant universities and research facilities plus 40 life science research nonprofits, most were within the city, as you can see in the image below. In the past, it’s been difficult for entrepreneurs to bridge that gulf between the creation of new technology and its commercialization.

Enter the bio-incubators and accelerator facilities, of which we found 16. Many of these are new facilities, as developers respond to the growing need for space to launch a new life science company in New York. The addition of this new infrastructure has made it much easier for entrepreneurs to start their operations – at RESI, our new panel called “Why NYC? Why Now?” will explore how this infrastructure has become a key building block for the city’s life science growth.

The other key factor required for NYC’s biotech scene to bloom? Capital. New York is awash with investment dollars, but in the past, little of that money has been focused on life science ventures specifically. Investors who are interested in biotech startups don’t necessarily have NYC on their map as a place to look for new companies. By bringing RESI to NYC and gathering together investors from all over the world, we hope to put New York firmly on the bio hub tour.

Hot Investor Mandate 1: Major Medical Device Corporation Invests in Series A – D Rounds

26 Oct

A global medical device company is looking for traditional M&A opportunities in mature businesses as well as strategic equity investments in early stage companies via a corporate venture fund, primarily focused on Series A through D rounds. Initial investments usually range from $2M – $3M with some capital reserved for follow on investments and are generally flexible in terms of structure, with no special rights attached. Although these investments are strategic in nature, the fund does look for financial returns. The firm looks to deploy around $20 – $30M annually into these early stage ventures, and is open to companies on a global basis.

The firm has four main business segments in orthopedic reconstruction, advanced wound management, sports medicine and ENT. The firm is open to any technologies within these areas, from services to medical devices and is beginning to look at healthcare IT solutions that have utility in these segments. The firm will look at technologies as early as prototype phase and looks to leverage their internal expertise to evaluate their viability. The company has no restrictions in terms of regulatory pathway and will look at class I through class III products.

The firm has preference for experienced management teams but has no strict company or management requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: Hospital System Invests in Digital Health Innovations

26 Oct

The investment arm of a non-profit hospital system affiliated with two leading medical schools is investing from a $15M fund, and usually writes checks in the $1 million range. The firm will participate mostly in Series A and B rounds but is open to considering earlier stage, non-revenue generating companies with highly disruptive technologies. Currently, the firm is focused only on USA-based investment opportunities.

The firm is seeking digital health companies with technologies that can provide significant value to their hospital system. The firm is most interested in those that address key organization priorities, which include (1) virtualization of care (i.e. telehealth), (2) operational efficiency, (3) patient and clinician experience of care. The organization is also interested in novel applications of technologies such as AI that may not impact healthcare in the short term, but may have a disruptive potential in the future. The organization is not interested in therapeutics, medical devices, or diagnostics companies.

The firm is looking to work with companies with experienced management teams. The firm does not act as a lead investor and only seeks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 3: Corporate Venture Capital Fund Invests in Therapeutics and Customer-Centered Health

26 Oct

The venture capital arm of a large global corporation is actively investing worldwide, and the firm’s US office invested $100m in 20 companies in 2016. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 4: Specialty Pharma Firm Seeks Later Stage Therapeutic Assets in Respiratory, Oncology and More

26 Oct

A specialty pharmaceutical company with offices in China and the US focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory. The company is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The company is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The company is actively seeking products from the US and Europe.

The firm has a primary focus in seeking products in Phase II/III or already been approved or launched in US or EU and in Surgery, Pediatric, Respiratory, ICU, Oncology and Nephrology areas. However, the company will also look into the products in Cardiovascular, Clinical nutrition and Pain management, but these are not our priority for now. Eddingpharm is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The company will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China. In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the company is looking for assets that have obtained regulatory approval in the US or Europe markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Book Your RESI NYC Partnering Meetings Starting on Monday October 23rd

19 Oct

By Natasha Eldridge, Director of RESI Conference Series, LSN


Next Monday, October 23rd, the RESI Partnering Platform will open for the first RESI NYC, and the hundreds of entrepreneurs and investors who are signed up for RESI will have the opportunity to start booking one-on-one meetings.

If you’ve signed up for RESI’s Premier Partnering Plus, you will be able to access deep profiles of investors and strategic players that can be used to ensure you are targeting the most relevant investors in attendance. As well as providing an extra tool to vet the firms you’re reaching out to, Premier Partnering Plus includes contact info to help reach investors and secure meetings. If you’re already registered and would like to talk about upgrading your registration, please contact us at

Beyond Partnering, RESI will offer 24 panels and workshops featuring more than 100 speakers focused on early-stage investment, and provide an engaging venue for ad-hoc networking on NYC’s up-and-coming biotech scene.

We hope you’re all ready to start filling out your dance card for RESI NYC. The price to attend RESI will increase by $200 after Friday, October 20th – if you’d like to take part in RESI Partnering, don’t delay in signing up.